Metformin HCl market is witnessing steady expansion, supported by new U.S. FDA approvals, increasing generic competition, and strategic product launches. As a cornerstone therapy for Type 2 Diabetes, metformin continues to drive strong activity among pharmaceutical companies aiming to strengthen their presence in the anti-diabetic segment.
A major development occurred in April 2026 when Lupin Limited received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in strengths of 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg. The company also received tentative approval for the 2.5 mg/1,000 mg strength. These products are bioequivalent to Xigduo XR and strengthen Lupin’s position in the U.S. diabetes market by expanding its complex generics portfolio.
Another important milestone came in November 2025 when Granules Life Sciences Private Limited secured its first U.S. FDA approval for Metformin HCl tablets. The product is manufactured at the Gagillapur facility in India and was approved following a successful pre-approval inspection. The company plans to launch the product in the U.S. market soon and is working on multi-site manufacturing strategies to ensure consistent supply and support long-term growth.
Product innovation is also contributing to market expansion. In July 2025, Camber Pharmaceuticals launched Metformin Hydrochloride Oral Solution, designed for patients aged 10 years and older who have difficulty swallowing tablets. This liquid formulation enhances patient compliance and serves as an effective adjunct to diet and exercise for glycemic control.
In addition, Aurobindo Pharma Limited received U.S. FDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in four strengths, targeting an estimated market opportunity of $514 million. The company secured 180 days of shared generic exclusivity as one of the first ANDA applicants with Paragraph IV certification. The product is manufactured at Unit-IV of APL Healthcare Limited and has been launched in the U.S., further expanding Aurobindo’s robust generics portfolio.
Overall, the metformin market continues to evolve through a combination of regulatory approvals, innovative formulations, and competitive generic entries. Companies such as Lupin, Granules Life Sciences, Camber Pharmaceuticals, and Aurobindo Pharma are actively driving growth by improving treatment accessibility and affordability. With the rising global burden of diabetes and continued innovation in drug delivery, the market is expected to maintain strong and steady momentum in the coming years.
